Generic Medicine Info
Indications and Dosage
Assessment of thyroid function and TSH reserve
Adult: 200 mcg given as single bolus dose.
Child: <12 yr: 1 mcg/kg as single dose. Dose may vary, consult local protocol.
Do not dilute solution.
Special Precautions
Caution in patients with bronchial asthma or other types of obstructive airway disease, myocardial ischaemia, severe hypothyroidism. To reduce incidence of hypotension, Protirelin should be given while the patient is lying down. Breast enlargement and leakage of milk have been reported in lactating women.
Adverse Reactions
Headache, lightheadedness, dizziness, nausea, stomach pain, strange taste, mouth dryness, urge to urinate, flushing, hypotension, transient increase in pulse rate and BP, rarely bronchospasm.
Symptoms of overdose have not been observed in patients receiving up to 1 mg of IV Protirelin.
Drug Interactions
Thyroid hormones, levodopa, phenothiazines, salicylates, bromocriptine, carbamazepine, lithium and pharmacological doses of corticosteroids may decrease TSH response to Protirelin. Increased TSH response may be observed when used with metoclopramide, amiodarone, theophyllines, and oestrogens use in men. May enhance response if overtreated with antithyroid drugs.
Mechanism of Action: Protirelin is a synthetic tripeptide hormone used as diagnostic test agent in assessing thyroid function and thyroid-stimulating hormone (TSH) reserve in the pituitary gland. It stimulates the release of TSH from the anterior pituitary gland, also causes concomitant rise in serum prolactin levels. It is used as diagnostic test for mild hyperthyroidism, ophthalmic Grave's disease, mild or preclinical hypothyroidism, hypopituitarism, and hypothalmic disease.
Distribution: Rapidly disappears from plasma after admin. When given via IV inj in healthy subjects, serum levels peak at about 20 min after admin.
Excretion: Excreted in urine (about 5.5%; within 30 min). Elimination half-life: About 5.3 min.
MIMS Class
Other Therapeutic Products
Disclaimer: This information is independently developed by MIMS based on Protirelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in